Skip to content
drillr.ai
Sign up

01177.HK

Sino Biopharmaceutical Limited

HKSE · Healthcare · Biotechnology · HK

HKD 5.47
−0.45%
Ask drillr

  • Sep 18, 2026, 04:30 UTC

    China Resources Pharmaceutical Group's subsidiary China Resources Pharmaceutical Commercial signed a strategic cooperation agreement with Sino Biopharmaceutical covering drug commercialization and distribution, supply chain coordination, drug development, market access, DTP pharmacies and patient disease management, targeting a cooperation scale of RMB 10 billion.

    Source:

  • Sep 18, 2026, 03:05 UTC

    Sino Biopharmaceutical's management reiterated its full-year guidance for double-digit year-on-year revenue growth, driven by licensing income and innovative drug sales.

    Source:

  • Sep 15, 2026, 23:31 UTC

    China Biopharmaceuticals announced that its subsidiary Chia Tai Tianqing Pharmaceutical Group's self-developed Class 1 innovative drug TQH2722 injection (IL-4Rα monoclonal antibody) had its new drug application accepted by the Center for Drug Evaluation (CDE) of China's National Medical Products Administration for moderate-to-severe atopic dermatitis in adults.

    Source:

  • Sep 15, 2026, 23:10 UTC

    Sino Biopharmaceutical's subsidiary Chia Tai Tianqing Pharmaceutical Group submitted a new drug application to China's Center for Drug Evaluation for its TQB2102 injection for HER2-low advanced breast cancer, which was accepted for review.

    Source:

  • Sep 14, 2026, 08:12 UTC

    Hong Kong stocks closed higher on September 14, 2026, with the Hang Seng Index up 111 points or 0.5% at 24,917, while the Hang Seng Tech Index slipped 2 points or 0.1% to 4,317 and the China Enterprises Index rose 38 points or 0.5% to 8,284 on turnover of HK$192.625 billion.

    Source:

  • Sep 14, 2026, 04:12 UTC

    Hong Kong stocks closed the morning session higher on September 14, 2026, with the Hang Seng Index up 87 points at 24,893 and the Hang Seng Tech Index up 7 points at 4,327.

    Source:

  • Sep 11, 2026, 08:43 UTC

    China Biologic Products Holdings (01177) agreed to acquire an additional 5% stake in Chia Tai Tianqing from its major shareholder for RMB 4.48 billion, raising its indirect holding from 60% to 65%.

    Source:

  • Sep 11, 2026, 08:12 UTC

    Hong Kong's Hang Seng Index closed down 148 points, or 0.6%, at 24,805, while the Hang Seng Tech Index fell 9 points, or 0.2%, to 4,320, with market turnover of HK$228.431 billion.

    Source:

  • Sep 8, 2026, 10:12 UTC

    China Biologic Products' subsidiary Chia Tai Tianqing presented preclinical data for its oral STAT6 degrader TQH5528 at the European Respiratory Society 2026 congress (ERS 2026) via an oral presentation and electronic poster.

    Source:

  • Sep 3, 2026, 12:41 UTC

    China Biopharmaceuticals' subsidiary Chia Tai Tianqing received FDA approval for its investigational new drug TQB6426, a GPC3 antibody-drug conjugate for advanced malignant tumors, to proceed with clinical trials.

    Source:

  • Aug 31, 2026, 10:14 UTC

    CIPLA and SBP Group signed an exclusive licensing agreement for the HER2 bispecific antibody-drug conjugate TQB2102.

    Source:

  • Aug 31, 2026, 00:03 UTC

    China Biopharmaceuticals announced Phase I clinical data for its LPA siRNA drug Kylo-11 at the 2026 European Society of Cardiology Congress and in The Lancet.

    Source:

  • Aug 28, 2026, 08:52 UTC

    China Biologic Products' subsidiary Laixinnuo Medical Technology received clinical trial approval from China's NMPA for its innovative drug LM-364 (Nectin-4 TME ADC) for advanced solid tumors, following FDA approval in April and trial initiation in Australia.

    Source:

  • Aug 28, 2026, 00:18 UTC

    China's National Healthcare Security Administration held a symposium on August 27, 2026, with 16 pharmaceutical companies to discuss industry development and gather opinions for the 15th Five-Year Plan period.

    Source:

  • Aug 21, 2026, 04:31 UTC

    China Biologic Products (01177.HK) shares rose 3.62% to HK$5.585 in morning trading on August 21, 2026, following its earnings release.

    Source:

  • Aug 20, 2026, 06:00 UTC

    Chinese AI startup TranscEngram raised several hundred million yuan in an angel round from investors including SBP Group, PDVC, Zhangjiang Hi-Tech Park, and HON-Flex.

    Source:

  • Aug 20, 2026, 04:01 UTC

    China Biopharmaceutical (01177.HK) reported first-half 2026 results with net profit up 1.4% year-on-year to RMB 3.44 billion, significantly beating market and Citi expectations, and revenue up 10.6% to RMB 19.44 billion, driven by strong innovative drug sales growth of 44.3% to RMB 8.79 billion.

    Source:

  • Aug 19, 2026, 08:51 UTC

    Sino Biopharmaceutical declared an interim dividend of HK$0.07 per share for the six months ended June 2026, up from HK$0.05 in the prior year.

    Source:

  • Jul 10, 2026, 19:44 UTC

    AI² Robotics raised about $735 million in a fresh financing round, pushing its valuation to about $2.8 billion.

    Source:

  • Jul 9, 2026, 06:41 UTC

    Sino Biopharmaceutical announced licensing agreements with GlaxoSmithKline for two approved respiratory products Trelegy and Anoro in China.

    Source:

  • Jul 7, 2026, 22:06 UTC

    China Biologic Pharmaceutical (Sino Biopharmaceutical) entered into an exclusive license agreement with AstraZeneca for TQC3721, granting AstraZeneca exclusive rights outside China, with upfront payment of $200 million and up to $1.9 billion in milestones plus tiered royalties.

    Source:

  • Jul 4, 2026, 11:52 UTC

    Hong Kong-listed companies, led by Tencent Holdings, AIA Group, and Xiaomi Corporation, have conducted share buybacks totaling over 900 billion Hong Kong dollars year-to-date, with June 2026 reaching a monthly record of over 300 billion Hong Kong dollars.

    Source:

  • Jun 12, 2026, 07:26 UTC

    Chia Tai Tianqing and Shionogi's drug Symproic (naldemedine) was approved for marketing in China by the NMPA for opioid-induced constipation.

    Source: